Nine Diagnostics co-founder Dr. Daniel Heller was featured in Women’s Health Magazine discussing why ovarian cancer remains so difficult to detect and how AI-enabled nanosensor technology could change the story. His research highlights the urgent funding gap in women’s health and demonstrates how nanosensors paired with AI can reveal hidden molecular “fingerprints” in blood, offering earlier and more accurate detection than current tools. This thought leadership underscores both the challenge and the promise of building next-generation diagnostics — the same vision driving Nine Diagnostics.
Nine Diagnostics co-founder and CEO Dr. Freddy T. Nguyen has been named a 2025 Scholar in Diagnostic Excellence by the National Academy of Medicine. This honor recognizes his leadership in advancing a patient-centered framework for diagnostic technology development, addressing challenges in bias, validation, and clinical implementation. His selection underscores both his national thought leadership and Nine Diagnostics’ mission to transform how medicine detects and treats disease.
Nine Diagnostics CEO and co-founder Dr. Freddy Nguyen presented at the MIT Health Science Forum 2025, an event bringing together MIT researchers, global industry leaders, and select startups to showcase transformative healthcare innovations. Highlighting our AI-powered nanosensor platform, Dr. Nguyen shared how Nine Diagnostics is advancing precision diagnostics for early detection and treatment monitoring. Selection to present at this prestigious forum underscores the company’s role in shaping the future of translational healthcare innovation.
Nine Diagnostics has been selected to join the American Cancer Society’s BrightEdge Entrepreneurs Program, a competitive initiative supporting oncology startups with high-impact potential. This recognition validates our vision to transform cancer detection and treatment monitoring with AI-enabled nanosensor technology. By joining BrightEdge’s network of mentors, investors, and industry leaders, Nine Diagnostics is positioned to accelerate innovation and bring game-changing solutions to the fight against cancer.
Nine Diagnostics co-founder Dr. Daniel Heller was featured in BBC News for his pioneering work on AI-enabled nanosensor technology to improve gynecological cancer detection. By combining carbon nanotube sensors with AI, his research is uncovering hidden molecular “fingerprints” in blood that could help doctors detect ovarian and other cancers earlier and more accurately. This recognition highlights Dr. Heller’s leadership in advancing transformative diagnostic technologies — the same vision driving Nine Diagnostics.
Nine Diagnostics has been selected for Merck Digital Sciences Studio Cohort 3, joining a premier accelerator supporting early-stage biomedical startups advancing AI and machine learning in healthcare. This milestone provides Nine Diagnostics with investment, mentorship, and strategic partnerships to accelerate its AI-enabled nanosensor platform — delivering precision insights for disease detection and treatment monitoring. The selection underscores our growing leadership in functional precision medicine and personalized healthcare innovation.
Nine Diagnostics has been awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, a milestone that provides lab space, mentorship, and resources to accelerate development of our AI-enabled nanosensor platform. This recognition underscores our commitment to advancing functional precision medicine and highlights Nine Diagnostics’ growing leadership in transforming early disease detection and treatment monitoring.
Nine Diagnostics co-founder Dr. Mijin Kim was recognized as a STAT Wunderkind, honoring her groundbreaking transition from physical chemistry to biomedical engineering. Her pioneering work with carbon nanotube nanosensors and machine learning is opening new frontiers in early cancer detection, including ovarian and other hard-to-screen cancers. This recognition highlights Dr. Kim’s scientific vision and the foundational role her research plays in Nine Diagnostics’ mission to transform diagnostics with nanosensor and AI technology.